Literature DB >> 12844324

Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Per Lønning1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12844324     DOI： 10.2165/00003088-200342070-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  114 in total

1.  Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

Authors:  J Geisler; S Detre; H Berntsen; L Ottestad; B Lindtjørn; M Dowsett; P Einstein Lønning
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors:  M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

3.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

Authors:  M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; N Zilembo; J L Dugardyn; C Nasurdi; R G Mennel; J Cervek; C Fowst; A Polli; E di Salle; A Arkhipov; G Piscitelli; L L Miller; G Massimini
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

4.  Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Authors:  M Dowsett; C Pfister; S R Johnston; D W Miles; S J Houston; J A Verbeek; H Gundacker; A Sioufi; I E Smith
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

5.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Quantitative determination of 4-hydroxy-4-androstene-3,17-dione (4-OHA), a potent aromatase inhibitor, in human plasma, using isotope dilution mass spectrometry.

Authors:  A Guarna; G Moneti; D Prucher; R Salerno; M Serio
Journal:  J Steroid Biochem       Date:  1989-05       Impact factor: 4.292

7.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

8.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors:  J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

9.  Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite.

Authors:  M Jarman; A B Foster; P E Goss; L J Griggs; I Howe; R C Coombes
Journal:  Biomed Mass Spectrom       Date:  1983-11

10.  A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.

Authors:  R Milsted; T Habeshaw; S Kaye; G Sangster; F Macbeth; J Campbell-Ferguson; D Smith; K Calman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
View more
  4 in total

Review 1.  Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.

Authors:  Lesley J Scott; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Letrozole: a review of its use in postmenopausal women with breast cancer.

Authors:  Dene Simpson; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.

Authors:  Yash Gupta; Dawid Maciorowski; Samantha E Zak; Krysten A Jones; Rahul S Kathayat; Saara-Anne Azizi; Raman Mathur; Catherine M Pearce; David J Ilc; Hamza Husein; Andrew S Herbert; Ajay Bharti; Brijesh Rathi; Ravi Durvasula; Daniel P Becker; Bryan C Dickinson; John M Dye; Prakasha Kempaiah
Journal:  Methods       Date:  2021-01-14       Impact factor: 3.608

4.  Sex-dependent effects of multiple acute concurrent stresses on memory: a role for hippocampal estrogens.

Authors:  Rachael E Hokenson; Yasmine H Alam; Annabel K Short; Sunhee Jung; Cholsoon Jang; Tallie Z Baram
Journal:  Front Behav Neurosci       Date:  2022-09-08       Impact factor: 3.617
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.